ストックスクリーナーアプリを入手
39.48
0.84%
0.33
プレマーケット:
38.80
-0.68
-1.72%
前日終値:
$39.15
開ける：
$38.77
24時間の取引高:
1.08M
Relative Volume:
0.58
時価総額：
$4.74B
収益：
$18.47M
当期純損益:
$-589.53M
株価収益率:
-7.5057
EPS:
-5.26
ネットキャッシュフロー:
$-399.80M
1週間 パフォーマンス:
+4.31%
1か月 パフォーマンス:
-12.09%
6か月 パフォーマンス:
-27.60%
1年 パフォーマンス:
-41.88%
1日の値動き範囲:
$38.41
$39.53
1週間の範囲:
$36.57
$40.22
52週間の値動き範囲:
$32.74
$68.76
Cytokinetics Inc Stock (CYTK) Company Profile
名前
Cytokinetics Inc
セクター
電話
(650) 624-3000
住所
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
CYTK を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
39.48 | 4.74B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-07 | 開始されました | Citigroup | Buy |
| 2025-01-22 | 開始されました | Stifel | Buy |
| 2024-11-08 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-08-13 | ダウングレード | Goldman | Buy → Neutral |
| 2024-01-24 | ダウングレード | UBS | Buy → Neutral |
| 2024-01-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | 開始されました | Goldman | Buy |
| 2023-11-07 | 開始されました | B. Riley Securities | Buy |
| 2023-08-15 | 開始されました | SVB Securities | Outperform |
| 2023-02-17 | 開始されました | BofA Securities | Neutral |
| 2022-12-23 | 繰り返されました | Needham | Buy |
| 2022-12-20 | 開始されました | Truist | Buy |
| 2022-10-11 | 開始されました | UBS | Buy |
| 2022-01-28 | 開始されました | Goldman | Buy |
| 2021-12-22 | 開始されました | Oppenheimer | Outperform |
| 2021-12-10 | 開始されました | JP Morgan | Overweight |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-03-12 | 開始されました | Wolfe Research | Outperform |
| 2021-02-18 | 開始されました | Barclays | Overweight |
| 2021-01-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-29 | 開始されました | Goldman | Neutral |
| 2020-07-10 | 開始されました | Raymond James | Strong Buy |
| 2020-05-05 | 開始されました | Mizuho | Buy |
| 2020-04-09 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-10 | 再開されました | Morgan Stanley | Equal-Weight |
| 2017-11-22 | 繰り返されました | Morgan Stanley | Overweight |
| 2017-11-22 | ダウングレード | Needham | Strong Buy → Buy |
| 2017-11-21 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-07-31 | 開始されました | Morgan Stanley | Overweight |
| 2017-03-08 | 開始されました | Rodman & Renshaw | Buy |
| 2017-02-06 | アップグレード | Needham | Buy → Strong Buy |
| 2016-12-16 | 開始されました | Cantor Fitzgerald | Overweight |
| 2016-07-28 | 繰り返されました | Needham | Buy |
| 2015-11-10 | 繰り返されました | FBR Capital | Outperform |
| 2015-11-09 | 繰り返されました | ROTH Capital | Buy |
| 2015-07-24 | 繰り返されました | MLV & Co | Buy |
| 2014-12-31 | 繰り返されました | ROTH Capital | Buy |
| 2014-11-04 | アップグレード | MLV & Co | Hold → Buy |
| 2014-04-28 | 繰り返されました | Needham | Buy |
すべてを表示
Cytokinetics Inc (CYTK) 最新ニュース
US FDA Expands Label For BMS’s Camzyos Days After Phase III Stumble - insights.citeline.com
Is Cytokinetics Inc. (NASDAQ:CYTK) the Best High Short Interest Stock to Buy Now? - Yahoo
10 Best High Short Interest Stocks to Buy Now - Insider Monkey
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Cytokinetics director John Henderson sells $123,325 in stock By Investing.com - Investing.com South Africa
Cytokinetics director John Henderson sells $123,325 in stock - Investing.com Australia
Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It - MSN
Cytokinetics (CYTK) Gains Favor as Key Trial by Bristol-Myers Fa - GuruFocus
Camzyos nHCM Failure Could Open Door To Threat From Cytokinetics’ Aficamten - insights.citeline.com
JMP maintains $78 target on Cytokinetics stock after trial update By Investing.com - Investing.com Canada
Cytokinetics falls after rival Bristol Myers' heart drug fails trial - TradingView
BofA Adjusts Price Target for Cytokinetics (CYTK) Amid Competiti - GuruFocus
Bristol Myers stumbles in bid to widen heart drug’s use - Yahoo Finance
Citi Analysts Include Cytokinetics (CYTK) in 2025 North America Focus List | CYTK Stock News - GuruFocus
Cytokinetics, IncorporatedCommon Stock (NQ: CYTK - FinancialContent
Cytokinetics CEO Robert Blum sells $183,850 in stock By Investing.com - Investing.com South Africa
Cytokinetics CEO Robert Blum sells $183,850 in stock - Investing.com Australia
Cytokinetics rises as Edgewise posts mid-stage trial data for heart disorder therapy - MSN
JMP reiterates Cytokinetics stock with $78 target on HCM trial optimism - Investing.com Canada
Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO - GlobeNewswire
Exclusive: Cardiometabolic biotech gets $57.5M Series B, with help from Cytokinetics - Endpoints News
Optimistic Buy Rating on Cytokinetics Driven by Promising Aficamten Trial Outcomes - TipRanks
Cytokinetics stock plunges to 52-week low of $33.67 By Investing.com - Investing.com Canada
Cytokinetics’ CK-4021586 improves cardiac function in HFpEF - BioWorld MedTech
Cytokinetics (NASDAQ:CYTK) Given "Buy" Rating at HC Wainwright - MarketBeat
Cytokinetics EVP sells $72,360 in stock By Investing.com - Investing.com South Africa
Cytokinetics EVP sells $72,360 in stock - Investing.com Australia
Cytokinetics' SWOT analysis: aficamten potential drives stock outlook - Investing.com
Cytokinetics at Needham Conference: Strategic Moves in Cardiovascular Health By Investing.com - Investing.com Canada
Cytokinetics CCO Andrew Callos sells $103k in stock By Investing.com - Investing.com India
Cytokinetics CCO Andrew Callos sells $103k in stock - Investing.com
Cytokinetics at Needham Conference: Strategic Moves in Cardiovascular Health - Investing.com
Cytokinetics director Robert Harrington sells shares worth $17,743 By Investing.com - Investing.com South Africa
Cytokinetics director Robert Harrington sells shares worth $17,743 - Investing.com Australia
H.C. Wainwright maintains $120 target on Cytokinetics stock By Investing.com - Investing.com Canada
Cytokinetics stock holds $78 target from JMP amid trial results By Investing.com - Investing.com Canada
Cantor Fitzgerald maintains overweight on Cytokinetics stock By Investing.com - Investing.com Canada
Cytokinetics stock holds $78 target from JMP amid trial results - Investing.com
CYTK Gains as EWTX Data and Fundraising Impact Stock Movement - GuruFocus
Why These Two Biotech Stocks Just Diverged - Investor's Business Daily
Edgewise Therapeutics Stock Plummets on Drug Trial 'Adverse Events' - Investopedia
Raymond James maintains Cytokinetics stock with $81 target By Investing.com - Investing.com UK
Winners and wishers: 9 potential Bay Area drug approvals coming this yearSan Francisco Business Times - The Business Journals
Cytokinetics stock rises on Edgewise data for lead drug (EWTX) - Seeking Alpha
Cytokinetics CEO compensation jumps 64%, thanks in large part to stock awardsSan Francisco Business Times - The Business Journals
Cytokinetics CEO Makes Major Stock Move! - TipRanks
Former Gilead legal star departs Cytokinetics as crucial FDA ruling approachesSan Francisco Business Times - The Business Journals
Cytokinetics to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Cytokinetics Leadership Takes Center Stage at Elite Needham Healthcare Conference - Stock Titan
Cytokinetics stock hits 52-week low at $40.49 amid market challenges - Investing.com UK
Cytokinetics Inc (CYTK) 財務データ
収益
当期純利益
現金流量
EPS
2.51%
大文字化:
|
ボリューム (24 時間):